Estimation of Measles Risk Using the World Health Organization Measles Programmatic Risk Assessment Tool, Iran

Overview

Journal Heliyon

Specialty Social Sciences

Date 2018 Nov 13

PMID 30417154

Citations 8

Authors

Abolfazl Mohammadbeigi

Seyed Mohsen Zahraei

Azadeh Asgarian

Sima Afrashteh

Narges Mohammadsalehi

Salman Khazaei

Hossein Ansari

Affiliations

Soon will be listed here.

Abstract

Introduction: Based on the World Health Organization (WHO) reports the EMRO countries did not reached to eradication of measles at 2010. This study aimed to estimate the risk of measles outbreak in different districts of Iran to identify high-risk areas based on WHO measles programmatic risk assessment tool.

Materials And Methods: The WHO measles programmatic risk assessment tool was used to estimate the overall risk of measles in 31 providences and 322 districts of Iran at 2017. The measles risk was calculated by a function of four indicator scores including population immunity, surveillance quality, program performance, and threat assessment and the overall risk of measles for each districts calculated. Then, the tool assigned each district a risk category of low, medium, high, or very high according to the overall risk score.

Results: Of the 322 districts in Iran, all districts were categorized as low risk and there was no very high risk, high risk and medium risk district in Iran. Twenty-six districts (7.4%) received to risk point higher than 20. Based on population immunity and program delivery performance indicators, all districts in Iarn were categorized as low risk and 92.86% of districts were in low risk category by surveillance quality indicator.

Conclusion: The overall risk of measles profile was categorized as low risk and Iranian practices for measles elimination is very good in comparing other studies in this area. However, more attempts should be conducted to sustaining the surveillance quality indicators in all districts.

Citing Articles

Assessing measles risk transmission in Iran: a utilization of the World Health Organization's programmatic risk assessment tool,2022.

Dashti E, Karami M, Zahraei S, Gharibnavaz H, Sabouri A, Zavareh F BMC Infect Dis. 2024; 24(1):1108.

PMID: 39369223 PMC: 11456239. DOI: 10.1186/s12879-024-09834-8.

[Stratification of risk areas for measles transmission: a systematic reviewEstratificación de las zonas de riesgo de transmisión del sarampión: revisión sistemática].

Conceicao P, Pedro A, Praca H, Dos Santos Y, Reis L, Gibson G Rev Panam Salud Publica. 2024; 48:e1.

PMID: 38226153 PMC: 10787521. DOI: 10.26633/RPSP.2024.1.

Evaluating Measles Incidence Rates Using Machine Learning and Time Series Methods in the Center of Iran, 1997-2020.

Nazari J, Fathi P, Sharahi N, Taheri M, Amini P, Almasi-Hashiani A Iran J Public Health. 2022; 51(4):904-912.

PMID: 35936521 PMC: 9288389. DOI: 10.18502/ijph.v51i4.9252.

Measles Elimination Successful and Its Relevant Challenges in Iran.

Hosseinalipour S, Mohammadbeigi A, Mohebi S, Saghafipour A, Arabshahi A, Mahdianpour F Int J Prev Med. 2022; 13:52.

PMID: 35706857 PMC: 9188879. DOI: 10.4103/ijpvm.IJPVM_334_20.

Spatial distribution of vaccine-preventable diseases in central Iran in 2015-2018: A GIS-based study.

Mohammadbeigi A, Saghafipour A, Jesri N, Tarkhan F, Jooshin M Heliyon. 2020; 6(9):e05102.

PMID: 33024873 PMC: 7527658. DOI: 10.1016/j.heliyon.2020.e05102.

References

Kriss J, De Wee R, Lam E, Kaiser R, Shibeshi M, Ndevaetela E . Development of the World Health Organization Measles Programmatic Risk Assessment Tool Using Experience from the 2009 Measles Outbreak in Namibia. Risk Anal. 2016; 37(6):1072-1081. DOI: 10.1111/risa.12544. View

Esteghamati A, Gouya M, Zahraei S, Dadras M, Rashidi A, Mahoney F . Progress in measles and rubella elimination in Iran. Pediatr Infect Dis J. 2007; 26(12):1137-41. DOI: 10.1097/INF.0b013e3181462090. View

Henao-Restrepo A, Strebel P, Hoekstra E, Birmingham M, Bilous J . Experience in global measles control, 1990-2001. J Infect Dis. 2003; 187 Suppl 1:S15-21. DOI: 10.1086/368273. View

Karami M, Zahraei S, Sabouri A, Soltanshahi R, Biderafsh A, Piri N . Documentation of Measles Elimination in Iran: Evidences from 2012 to 2014. J Res Health Sci. 2017; 17(3):e00387. View

Zahraei S, Mohammadbeigi A, Mohammadsalehi N, Sabouri A, Afrashteh S, Jang S . Monitoring of Surveillance Quality Indicators of Measles in Iranian Districts: Analysis of Measles Surveillance System 2014-2016. J Res Health Sci. 2018; 18(3):e00418. PMC: 6941647. View

Salimi V, Abbasi S, Zahraei S, Fatemi-Nasab G, Adjaminezhad-Fard F, Shadab A . Implementation of a national measles elimination program in Iran: Phylogenetic analysis of measles virus strains isolated during 2010-2012 outbreaks. PLoS One. 2014; 9(4):e94846. PMC: 3988093. DOI: 10.1371/journal.pone.0094846. View

Kriss J, Stanescu A, Pistol A, Butu C, Goodson J . The World Health Organization Measles Programmatic Risk Assessment Tool-Romania, 2015. Risk Anal. 2016; 37(6):1096-1107. PMC: 9245689. DOI: 10.1111/risa.12669. View

Mohammadbeigi A, Mokhtari M, Zahraei S, Eshrati B, Rejali M . Survival Analysis for Predictive Factors of Delay Vaccination in Iranian Children. Int J Prev Med. 2016; 6:119. PMC: 4736051. DOI: 10.4103/2008-7802.170868. View

Rejali M, Mohammadbeigi A, Mokhtari M, Zahraei S, Eshrati B . Timing and delay in children vaccination; evaluation of expanded program of immunization in outskirt of Iranian cities. J Res Health Sci. 2015; 15(1):54-8. View

10.

Zahraei S, Eshrati B, Gouya M, Mohammadbeigi A, Kamran A . Is there still an immunity gap in high-level national immunization coverage, Iran?. Arch Iran Med. 2014; 17(10):698-701. DOI: 0141710/AIM.0011. View

11.

Izadi S, Zahraie S, Sartipi M . An investigation into a measles outbreak in southeast Iran. Jpn J Infect Dis. 2012; 65(1):45-51. View

12.

Ducusin M, de Quiroz-Castro M, Roesel S, Garcia L, Cecilio-Elfa D, Schluter W . Using the World Health Organization Measles Programmatic Risk Assessment Tool for Monitoring of Supplemental Immunization Activities in the Philippines. Risk Anal. 2015; 37(6):1082-1095. DOI: 10.1111/risa.12404. View

13.

Lam E, Schluter W, Masresha B, Teleb N, Bravo-Alcantara P, Shefer A . Development of a District-Level Programmatic Assessment Tool for Risk of Measles Virus Transmission. Risk Anal. 2015; 37(6):1052-1062. PMC: 10256314. DOI: 10.1111/risa.12409. View

14.

Davoodian P, Atashabparvar A, Dadvand H, Hosseinpour M, Daryanavard A, Safari R . A report of outbreaks of measles on the southern coast of Iran from 2009 to 2015. Electron Physician. 2017; 9(3):3997-4002. PMC: 5407234. DOI: 10.19082/3997. View

15.

Zahraei S, Gouya M, Azad T, Soltanshahi R, Sabouri A, Naouri B . Successful control and impending elimination of measles in the Islamic Republic of Iran. J Infect Dis. 2011; 204 Suppl 1:S305-11. DOI: 10.1093/infdis/jir076. View

16.

Izadi S, Zahraei S, Mokhtari-Azad T . Seroprevalence of antibodies to measles and rubella eight months after a vaccination campaign in the southeast of Iran. Hum Vaccin Immunother. 2018; 14(6):1412-1416. PMC: 6037465. DOI: 10.1080/21645515.2018.1436920. View

17.

Jadidi R, Mohammadbeigi A, Mohammadsalehi N, Ansari H, Ghaderi E . Inequity in Timeliness of MMR Vaccination in Children Living in the Suburbs of Iranian Cities. Int J Biomed Sci. 2015; 11(2):93-8. PMC: 4502739. View